In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elekta’s Project Atlantic: A New Blue Ocean For Radiation Therapy

Executive Summary

Elekta AB is counting on rapid uptake of its new first-generation MRI-guided radiation therapy technology after its CE-marking and FDA clearance, anticipated in 2017. The so-called Project Atlantic combines high-field real-time MR imaging with state-of-the-art linear technology that, in the words of Elekta president and CEO Niklas Savander, will take the standard of care to the next level.

You may also be interested in...



Start-Ups Reduce Radiation Exposure

The use of cancer radiation therapy and interventional fluoroscopy is expanding rapidly, and start-ups are pioneering innovative technologies to capitalize on the industry-wide movement to reduce radiation exposure and improve outcomes. Profiles of ControlRad Systems, Nanovi, and SoniTrack Systems.

Elekta: Growing from the Head Down

Elekta established its reputation with the Leksell Gamma Knife for neurosurgery. Now, after a turnaround, it is expanding into a comprehensive cancer care company.

UK MHRA In The Spotlight As Cumberlege Review Puts Medtech Safety At The Top Of Health Agenda

The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel